Yu Xuefeng, centro co-fondatore, Presidente e CEO di CanSino Biologics Inc., pone durante la cerimonia per la quotazione di cinese azienda biotech CanSino

• Collaboratore: Imaginechina Limited / Alamy Foto Stock
• ID dell’immagine: W5GF22
• Dimensioni dei file: 57,1 MB (3,1 MB Download compresso)
• Liberatorie: Modello - no | Proprietà - no
• Dimensioni: 5472 x 3648 px | 46,3 x 30,9 cm | 18,2 x 12,2 inches | 300dpi
• Data acquisizione: 28 marzo 2019
• Fotografo: Imaginechina

Altre informazioni

Yu Xuefeng, center, co-founder, Chairman and CEO of CanSino Biologics Inc., poses during the ceremony for the listing of Chinese biotech firm CanSino Biologics Inc. at the Hong Kong Stock Exchange (HKEX) in Hong Kong, China, 28 March 2019. Shares in Chinese biotech firm CanSino Biologics Inc. were set to open at HK$21 ($2.6) in their Hong Kong debut on Thursday (28 March 2019). CanSino made headlines in 2017 when China¯s regulator approved its vaccine for the deadly Ebola virus that ravaged parts of Western Africa in 2014 and 2015. That vaccine was co-developed with the Chinese military and was one of a number of similar products being created globally to fight the disease.

Parole chiave associate all'immagine

• biologico cansino
• biontech
• china
• cinese
• l'hong kong
• la tecnologia
• listing
• tec